These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22262618)

  • 1. A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent.
    Fireman B; Toh S; Butler MG; Go AS; Joffe HV; Graham DJ; Nelson JC; Daniel GW; Selby JV
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():282-90. PubMed ID: 22262618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study.
    Toh S; Reichman ME; Graham DJ; Hampp C; Zhang R; Butler MG; Iyer A; Rucker M; Pimentel M; Hamilton J; Lendle S; Fireman BH;
    Diabetes Care; 2018 Jan; 41(1):39-48. PubMed ID: 29122893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.
    Toh S; Hampp C; Reichman ME; Graham DJ; Balakrishnan S; Pucino F; Hamilton J; Lendle S; Iyer A; Rucker M; Pimentel M; Nathwani N; Griffin MR; Brown NJ; Fireman BH
    Ann Intern Med; 2016 Jun; 164(11):705-14. PubMed ID: 27110660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA's first active medical product surveillance eyes antidiabetic-MI link.
    Thompson CA
    Am J Health Syst Pharm; 2011 Apr; 68(7):550-1. PubMed ID: 21411791
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine.
    Rhoads GG; Kosiborod M; Nesto RW; Fonseca VA; Lu SE; Zhang Q; Foody JM
    Am J Cardiol; 2009 Oct; 104(7):910-6. PubMed ID: 19766755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions.
    Prescrire Int; 2011 Feb; 20(113):33-7. PubMed ID: 21488586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini-Sentinel pilot.
    Cook AJ; Tiwari RC; Wellman RD; Heckbert SR; Li L; Heagerty P; Marsh T; Nelson JC
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():72-81. PubMed ID: 22262595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.
    Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Price DL; Chen R; Udell J; Raz I
    Am Heart J; 2011 Nov; 162(5):818-825.e6. PubMed ID: 22093196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity analysis of methods for active surveillance of acute myocardial infarction using electronic databases.
    Li X; Girman CJ; Ofner S; Shen C; Brodovicz KG; Simonaitis L; Santanello N
    Epidemiology; 2015 Jan; 26(1):130-2. PubMed ID: 25390030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    IDrugs; 2008 Dec; 11(12):906-17. PubMed ID: 19051153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
    Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
    Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of exposure accrual on sequential postmarket evaluations: a simulation study.
    Maro JC; Brown JS
    Pharmacoepidemiol Drug Saf; 2011 Nov; 20(11):1184-91. PubMed ID: 22020903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction.
    Platt R; Carnahan RM; Brown JS; Chrischilles E; Curtis LH; Hennessy S; Nelson JC; Racoosin JA; Robb M; Schneeweiss S; Toh S; Weiner MG
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():1-8. PubMed ID: 22262586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies.
    Lo Re V; Haynes K; Ming EE; Wood Ives J; Horne LN; Fortier K; Carbonari DM; Hennessy S; Cardillo S; Reese PP; Reddy KR; Margolis D; Apter A; Kimmel SE; Roy J; Freeman CP; Razzaghi H; Holick CN; Esposito DB; Van Staa TP; Bhullar H; Strom BL
    Pharmacoepidemiol Drug Saf; 2012 Nov; 21(11):1202-15. PubMed ID: 22763953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ
    Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system.
    Rassen JA; Schneeweiss S
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():41-9. PubMed ID: 22262592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors and Sudden Cardiac Arrest and Ventricular Arrhythmia: Population-Based Cohort Studies.
    Dawwas GK; Hennessy S; Brensinger CM; Deo R; Bilker WB; Soprano SE; Dhopeshwarkar N; Flory JH; Bloomgarden ZT; Aquilante CL; Kimmel SE; Leonard CE
    Clin Pharmacol Ther; 2022 Jan; 111(1):227-242. PubMed ID: 34331322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DPP-4 inhibitors and their potential role in the management of type 2 diabetes.
    Barnett A
    Int J Clin Pract; 2006 Nov; 60(11):1454-70. PubMed ID: 17073841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.
    Stockl KM; Le L; Zhang S; Harada AS
    Pharmacoepidemiol Drug Saf; 2009 Feb; 18(2):166-74. PubMed ID: 19109802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.